PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
20 déc. 2024 16h55 HE
|
PharmAla Biotech
PharmAla files audited financials for year ended August 31, 2024, completes continuance and oversubscribed private placement
PharmAla Announces Private Placement
13 déc. 2024 09h25 HE
|
PharmAla Biotech
PharmAla announces private placement financing
Psychedelic Science 2025 Conference Announces Workshops, Holiday Sale, and Scholarship Deadline
05 déc. 2024 15h44 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
World’s leading psychedelic conference kicks off with workshops from leaders in science, medicine, therapy, policy, Indigenous medicine, and societyUpcoming deadline: speaker submissions, initial...
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
14 nov. 2024 09h20 HE
|
PharmAla Biotech
PharmAla reaches agreement in principle to trade with a clinical trial to trade its LaNeo MDMA for a data license to the trial outcomes.
PharmAla to supply LaNeo MDMA for Clinical Trial at Yale
07 nov. 2024 09h20 HE
|
PharmAla Biotech
PharmAla to supply Yale University with MDMA for clinical trial
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
21 oct. 2024 09h25 HE
|
PharmAla Biotech
PharmAla contracted to sell MDMA to Mt. Sinai Hospital, NY. Terminates Contract with CCrest Labs.
PharmAla Launches MDMA Clinical Trial Tool for Researchers
22 août 2024 09h07 HE
|
PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
29 mai 2024 08h00 HE
|
Optimi Health Corp.
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
22 mai 2024 08h30 HE
|
Optimi Health Corp.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
14 mai 2024 08h00 HE
|
Optimi Health Corp.
Optimi Health Receives Certificate of Analysis For GMP MDMA 40mg and 60mg MDMA Capsules.